BRAF and melanoma: It has been speculated that inhibition of MCL-1 through miR-32 may represent an efficient therapy for melanoma, regardless of its mutational status (NRAS, BRAF or PTEN), as it was discovered to exhibit synergistic effects with vemurafenib [123].